JP2023527411A5 - - Google Patents
Info
- Publication number
- JP2023527411A5 JP2023527411A5 JP2022573207A JP2022573207A JP2023527411A5 JP 2023527411 A5 JP2023527411 A5 JP 2023527411A5 JP 2022573207 A JP2022573207 A JP 2022573207A JP 2022573207 A JP2022573207 A JP 2022573207A JP 2023527411 A5 JP2023527411 A5 JP 2023527411A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cancer
- combination according
- inhibitors
- flt3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032675P | 2020-05-31 | 2020-05-31 | |
| US63/032,675 | 2020-05-31 | ||
| US202063060595P | 2020-08-03 | 2020-08-03 | |
| US63/060,595 | 2020-08-03 | ||
| US202063063892P | 2020-08-10 | 2020-08-10 | |
| US63/063,892 | 2020-08-10 | ||
| US202063198864P | 2020-11-18 | 2020-11-18 | |
| US63/198,864 | 2020-11-18 | ||
| PCT/US2021/034773 WO2021247396A1 (en) | 2020-05-31 | 2021-05-28 | Compounds and methods for reduction of cancer cell burden and protection of normal hematopoiesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527411A JP2023527411A (ja) | 2023-06-28 |
| JP2023527411A5 true JP2023527411A5 (enExample) | 2024-06-05 |
Family
ID=76624176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022573207A Pending JP2023527411A (ja) | 2020-05-31 | 2021-05-28 | がん細胞の負荷を減少させ、正常な造血を保護するための化合物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230165882A1 (enExample) |
| EP (1) | EP4157285A1 (enExample) |
| JP (1) | JP2023527411A (enExample) |
| CN (1) | CN115666584A (enExample) |
| WO (1) | WO2021247396A1 (enExample) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2264043T1 (en) | 2005-09-02 | 2018-01-31 | Glycomimetics, Inc. | HETEROBIFUNCTIONAL PAN-SELECTINE INHIBITORS |
| AU2008336249B2 (en) | 2007-12-10 | 2015-01-29 | The University Of Queensland | Treatment and prophylaxis |
| AU2010241807B2 (en) | 2009-05-01 | 2014-08-14 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors |
| EP2794626B3 (en) | 2011-12-22 | 2020-08-05 | GlycoMimetics, Inc. | E-selectin antagonist compounds |
| EP3062809B1 (en) * | 2013-10-31 | 2020-07-08 | Biokine Therapeutics Ltd. | A cxcr4 peptide inhibitor for use in treating acute myeloid leukemia with a flt3 mutation |
| CN107108679B (zh) | 2014-12-03 | 2020-10-23 | 糖模拟物有限公司 | E-选择蛋白和cxcr4趋化因子受体的异双官能抑制剂 |
| EP3383882A1 (en) | 2015-12-02 | 2018-10-10 | GlycoMimetics, Inc. | Heterobifunctional pan-selectin antagonists having a triazole linker |
| US11433086B2 (en) * | 2016-08-08 | 2022-09-06 | Glycomimetics, Inc. | Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4 |
| BR112019006642A2 (pt) | 2016-10-07 | 2019-07-02 | Glycomimetics Inc | antagonistas multiméricos de e-selectina altamente potentes |
| US11548908B2 (en) | 2017-12-29 | 2023-01-10 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| CA3136661A1 (en) | 2019-04-24 | 2020-10-29 | Glycomimetics, Inc. | Galactose-linked multimeric glycomimetic inhibitors of e-selectins, galectin-3, and/or cxcr4 chemokine receptors |
| US20220220144A1 (en) | 2019-04-24 | 2022-07-14 | Glycomimetics, Inc. | Multimeric pan-selectin antagonists |
| CN114341368A (zh) | 2019-07-12 | 2022-04-12 | 糖模拟物有限公司 | 使用基因表达作为多种肿瘤类型的e-选择素抑制剂功效和临床结果的指标的方法 |
-
2021
- 2021-05-28 WO PCT/US2021/034773 patent/WO2021247396A1/en not_active Ceased
- 2021-05-28 JP JP2022573207A patent/JP2023527411A/ja active Pending
- 2021-05-28 EP EP21735031.3A patent/EP4157285A1/en active Pending
- 2021-05-28 US US17/998,942 patent/US20230165882A1/en active Pending
- 2021-05-28 CN CN202180038537.5A patent/CN115666584A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | A phase II study of avelumab monotherapy in patients with mismatch repair–deficient/microsatellite instability–high or POLE-mutated metastatic or unresectable colorectal cancer | |
| Garcia-Carbonero et al. | Advances in the treatment of gastroenteropancreatic neuroendocrine carcinomas: are we moving forward? | |
| CN121604965A (zh) | 药物组合物及其应用 | |
| Mosquera et al. | Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials | |
| CA3108236A1 (en) | Methods and compositions for inhibition of egf/egfr pathway in combination with anaplastic lymphoma kinase inhibitors | |
| CN105120663A (zh) | 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物 | |
| Parikh et al. | A pooled analysis of two phase II trials evaluating metformin plus platinum-based chemotherapy in advanced non-small cell lung cancer | |
| Yunianto et al. | Potential drug repurposing of ruxolitinib to inhibit the JAK/STAT pathway for the treatment of patients with epithelial ovarian cancer | |
| Liu et al. | Anti-angiogenic therapy in ovarian cancer: current situation & prospects | |
| Shah et al. | Multicenter Phase II study of cabazitaxel in advanced gastroesophageal cancer: association of HER2 expression and M2-like tumor-associated macrophages with patient outcome | |
| Kim et al. | A phase II trial of nintedanib in patients with metastatic or recurrent head and neck squamous cell carcinoma: in-depth analysis of nintedanib arm from the KCSG HN 15-16 TRIUMPH trial | |
| Jin et al. | Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment | |
| Kawai et al. | Phase I/II study of preoperative chemoradiotherapy with TEGAFIRI for locally advanced rectal cancer | |
| Meng et al. | Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial | |
| Kwon et al. | Emerging agents for the treatment of metastatic urothelial cancer | |
| Sachdeva et al. | Controversies in the management of clear cell carcinoma of the uterus and ovary | |
| CN115245514A (zh) | 一种治疗非小细胞肺癌的药物组合物 | |
| Duenas-Gonzalez et al. | Pharmacotherapy options for locally advanced and advanced cervical cancer | |
| Peterson | Drug therapy of cancer | |
| Koo et al. | Varlitinib and paclitaxel for EGFR/HER2 co-expressing advanced gastric cancer: a multicenter phase Ib/II study (K-MASTER-13) | |
| JP2025513929A5 (enExample) | ||
| Barsouk et al. | Patient with mediastinal carcinoma of unknown primary with RET fusion achieves durable response with RET inhibition | |
| Lu et al. | Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, phase II study | |
| Hack et al. | Augmenting anticancer immunity through combined targeting of angiogenic and PD-1 | |
| Vandenput et al. | Limited clinical benefit from trastuzumab in recurrent endometrial cancer: two case reports |